{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,14]],"date-time":"2026-11-14T20:47:54Z","timestamp":1794689274110,"version":"4.9.1"},"reference-count":42,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2025,1,1]],"date-time":"2025-01-01T00:00:00Z","timestamp":1735689600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,1,1]],"date-time":"2025-01-01T00:00:00Z","timestamp":1735689600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,11,19]],"date-time":"2024-11-19T00:00:00Z","timestamp":1731974400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Cytokine"],"published-print":{"date-parts":[[2025,1]]},"DOI":"10.1016\/j.cyto.2024.156814","type":"journal-article","created":{"date-parts":[[2024,11,27]],"date-time":"2024-11-27T01:08:47Z","timestamp":1732669727000},"page":"156814","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":6,"special_numbering":"C","title":["Predictive cytokines of omalizumab in the treatment of chronic spontaneous urticaria"],"prefix":"10.1016","volume":"185","author":[{"given":"Ping","family":"Ji","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hao","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yaqi","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lin","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yin","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Guanghui","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rongfei","family":"Zhu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.cyto.2024.156814_bb0005","doi-asserted-by":"crossref","first-page":"734","DOI":"10.1111\/all.15090","article-title":"The international EAACI\/GA(2)LEN\/EuroGuiDerm\/APAAACI guideline for the definition, classification, diagnosis, and management of urticaria","volume":"77","author":"Zuberbier","year":"2022","journal-title":"Allergy"},{"key":"10.1016\/j.cyto.2024.156814_bb0010","doi-asserted-by":"crossref","first-page":"423","DOI":"10.1111\/all.14037","article-title":"Prevalence of chronic urticaria in children and adults across the globe: systematic review with meta-analysis","volume":"75","author":"Fricke","year":"2020","journal-title":"Allergy"},{"key":"10.1016\/j.cyto.2024.156814_bb0015","doi-asserted-by":"crossref","first-page":"630","DOI":"10.1111\/pai.12910","article-title":"Prevalence and clinical characteristics of chronic spontaneous urticaria in pediatric patients","volume":"29","author":"Balp","year":"2018","journal-title":"Pediat Allerg Imm-Uk."},{"key":"10.1016\/j.cyto.2024.156814_bb0020","doi-asserted-by":"crossref","first-page":"976","DOI":"10.1111\/bjd.16105","article-title":"Prevalence and incidence of chronic spontaneous urticaria in the entire Korean adult population","volume":"178","author":"Kim","year":"2018","journal-title":"Brit. J. Dermatol."},{"key":"10.1016\/j.cyto.2024.156814_bb0025","doi-asserted-by":"crossref","first-page":"321","DOI":"10.2340\/00015555-3104","article-title":"The prevalence of atopic dermatitis and chronic spontaneous Urticaria are associated with parental socioeconomic status in adolescents in China","volume":"99","author":"Xiao","year":"2019","journal-title":"Acta Derm-Venereol."},{"key":"10.1016\/j.cyto.2024.156814_bb0030","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1046\/j.1365-2133.1997.d01-1168.x","article-title":"The impact of chronic urticaria on the quality of life","volume":"136","author":"O\u2019Donnell","year":"1997","journal-title":"Brit. J. Dermatol."},{"key":"10.1016\/j.cyto.2024.156814_bb0035","doi-asserted-by":"crossref","first-page":"621","DOI":"10.1034\/j.1398-9995.2003.00091.x","article-title":"Quality of life and patients\u2019 satisfaction in chronic urticaria and respiratory allergy","volume":"58","author":"Baiardini","year":"2003","journal-title":"Allergy"},{"key":"10.1016\/j.cyto.2024.156814_bb0040","doi-asserted-by":"crossref","first-page":"2195","DOI":"10.1016\/j.jaip.2021.03.033","article-title":"The pathogenesis of chronic spontaneous Urticaria: the role of infiltrating cells","volume":"9","author":"Gimenez-Arnau","year":"2021","journal-title":"J. Aller. Cl. Imm-Pract."},{"key":"10.1016\/j.cyto.2024.156814_bb0045","doi-asserted-by":"crossref","first-page":"471","DOI":"10.1165\/ajrcmb.10.5.8179909","article-title":"Interleukin-4, \u22125, and \u22126 and tumor necrosis factor-alpha in normal and asthmatic airways: evidence for the human mast cell as a source of these cytokines","volume":"10","author":"Bradding","year":"1994","journal-title":"Am. J. Resp. Cell. Mol."},{"key":"10.1016\/j.cyto.2024.156814_bb0050","first-page":"146","article-title":"Determination of dermatology life quality index, and serum C-reactive protein and plasma interleukin-6 levels in patients with chronic urticaria","volume":"30","author":"Ucmak","year":"2013","journal-title":"Postep Derm Alergol."},{"key":"10.1016\/j.cyto.2024.156814_bb0055","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1007\/s40629-015-0039-3","article-title":"Th22 cells in allergic disease","volume":"24","author":"Eyerich","year":"2015","journal-title":"Allergo J. Int."},{"key":"10.1016\/j.cyto.2024.156814_bb0060","doi-asserted-by":"crossref","first-page":"1582","DOI":"10.1111\/all.14318","article-title":"Type 2 immunity in the skin and lungs","volume":"75","author":"Akdis","year":"2020","journal-title":"Allergy"},{"key":"10.1016\/j.cyto.2024.156814_bb0065","doi-asserted-by":"crossref","first-page":"441","DOI":"10.1111\/jdv.14541","article-title":"Different expression patterns of plasma Th1-, Th2-, Th17- and Th22-related cytokines correlate with serum autoreactivity and allergen sensitivity in chronic spontaneous urticaria","volume":"32","author":"Chen","year":"2018","journal-title":"J. Eur. Acad. Dermatol."},{"key":"10.1016\/j.cyto.2024.156814_bb0070","doi-asserted-by":"crossref","first-page":"3","DOI":"10.5826\/dpc.0301a02","article-title":"Notalgia paresthetica: the unreachable itch","volume":"3","author":"Ellis","year":"2013","journal-title":"Dermatol. Pract. Conce."},{"key":"10.1016\/j.cyto.2024.156814_bb0075","doi-asserted-by":"crossref","first-page":"A611","DOI":"10.1016\/j.jval.2014.08.2140","article-title":"Categorical health states in chronic spontaneous Urticaria (Csu) based on the weekly Urticaria activity score (Uas7): are they distinct, discriminative, and reproducible?","volume":"17","author":"Stull","year":"2014","journal-title":"Value Health"},{"key":"10.1016\/j.cyto.2024.156814_bb0080","doi-asserted-by":"crossref","first-page":"705","DOI":"10.1111\/all.13345","article-title":"The clinical response to omalizumab in chronic spontaneous urticaria patients is linked to and predicted by IgE levels and their change","volume":"73","author":"Ertas","year":"2018","journal-title":"Allergy"},{"key":"10.1016\/j.cyto.2024.156814_bb0085","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1038\/jid.2014.306","article-title":"Efficacy and safety of omalizumab in patients with chronic idiopathic\/spontaneous urticaria who remain symptomatic on H1 antihistamines: a randomized, placebo-controlled study","volume":"135","author":"Saini","year":"2015","journal-title":"J. Invest. Dermatol."},{"key":"10.1016\/j.cyto.2024.156814_bb0090","article-title":"Cytokine Profiles of Chronic Urticaria Patients and The Effect of Omalizumab Treatment","volume":"13","author":"Can","year":"2023","journal-title":"Dermatol. Pract. Conce."},{"key":"10.1016\/j.cyto.2024.156814_bb0095","doi-asserted-by":"crossref","first-page":"590","DOI":"10.1111\/ijd.14812","article-title":"IFN-gamma\/IL-6 and related cytokines in chronic spontaneous urticaria: evaluation of their pathogenetic role and changes during omalizumab therapy","volume":"59","author":"Grieco","year":"2020","journal-title":"Int. J. Dermatol."},{"key":"10.1016\/j.cyto.2024.156814_bb0100","doi-asserted-by":"crossref","first-page":"455","DOI":"10.1684\/ejd.2017.3085","article-title":"Expert opinion: defining response to omalizumab in patients with chronic spontaneous urticaria","volume":"27","author":"Ferrer","year":"2017","journal-title":"Eur. J. Dermatol."},{"key":"10.1016\/j.cyto.2024.156814_bb0105","doi-asserted-by":"crossref","first-page":"210","DOI":"10.1111\/j.1365-2230.1994.tb01167.x","article-title":"Dermatology Life Quality Index (DLQI)--a simple practical measure for routine clinical use","volume":"19","author":"Finlay","year":"1994","journal-title":"Clin. Exp. Dermatol."},{"key":"10.1016\/j.cyto.2024.156814_bb0110","doi-asserted-by":"crossref","first-page":"924","DOI":"10.1056\/NEJMoa1215372","article-title":"Omalizumab for the treatment of chronic idiopathic or spontaneous urticaria","volume":"368","author":"Maurer","year":"2013","journal-title":"New Engl J Med."},{"key":"10.1016\/j.cyto.2024.156814_bb0115","doi-asserted-by":"crossref","first-page":"879","DOI":"10.1172\/JCI119252","article-title":"The effect of intravenous administration of a chimeric anti-IgE antibody on serum IgE levels in atopic subjects: efficacy, safety, and pharmacokinetics","volume":"99","author":"Corne","year":"1997","journal-title":"J. Clin. Invest."},{"key":"10.1016\/j.cyto.2024.156814_bb0120","doi-asserted-by":"crossref","first-page":"1386","DOI":"10.1016\/j.jaip.2017.10.030","article-title":"Serum IgE as an immunological marker to predict response to omalizumab treatment in symptomatic chronic urticaria","volume":"6","author":"Straesser","year":"2018","journal-title":"J. Aller. Cl. Imm-Pract."},{"key":"10.1016\/j.cyto.2024.156814_bb0125","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1016\/j.jdermsci.2013.08.011","article-title":"Omalizumab is an effective and rapidly acting therapy in difficult-to-treat chronic urticaria: a retrospective clinical analysis","volume":"73","author":"Metz","year":"2014","journal-title":"J. Dermatol. Sci."},{"key":"10.1016\/j.cyto.2024.156814_bb0130","doi-asserted-by":"crossref","first-page":"735","DOI":"10.1111\/ced.13173","article-title":"Long-term management of chronic spontaneous urticaria with omalizumab","volume":"42","author":"Pinto","year":"2017","journal-title":"Clin. Exp. Dermatol."},{"key":"10.1016\/j.cyto.2024.156814_bb0135","doi-asserted-by":"crossref","first-page":"1761","DOI":"10.1111\/jdv.15045","article-title":"Effectiveness of omalizumab in chronic spontaneous urticaria assessed with patient-reported outcomes: a prospective study","volume":"32","author":"Ghazanfar","year":"2018","journal-title":"J. Eur. Acad. Dermatol."},{"key":"10.1016\/j.cyto.2024.156814_bb0140","doi-asserted-by":"crossref","first-page":"1268","DOI":"10.4049\/jimmunol.1002677","article-title":"IL-2-controlled expression of multiple T cell trafficking genes and Th2 cytokines in the regulatory T cell-deficient scurfy mice: implication to multiorgan inflammation and control of skin and lung inflammation","volume":"186","author":"Sharma","year":"2011","journal-title":"J. Immunol."},{"key":"10.1016\/j.cyto.2024.156814_bb0145","doi-asserted-by":"crossref","DOI":"10.1016\/j.clim.2023.109247","article-title":"Consecutive injections of low-dose interleukin-2 improve symptoms and disease control in patients with chronic spontaneous urticaria","volume":"247","author":"Wang","year":"2023","journal-title":"Clin. Immunol."},{"key":"10.1016\/j.cyto.2024.156814_bb0150","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1016\/j.jaut.2011.01.001","article-title":"IL-2: a two-faced master regulator of autoimmunity","volume":"36","author":"Sharma","year":"2011","journal-title":"J. Autoimmun."},{"key":"10.1016\/j.cyto.2024.156814_bb0155","doi-asserted-by":"crossref","first-page":"2320","DOI":"10.1111\/all.14067","article-title":"Recent developments and highlights in allergic rhinitis","volume":"74","author":"Meng","year":"2019","journal-title":"Allergy"},{"key":"10.1016\/j.cyto.2024.156814_bb0160","doi-asserted-by":"crossref","first-page":"300","DOI":"10.1016\/j.jaci.2017.02.038","article-title":"Type 2 innate lymphoid cells disrupt bronchial epithelial barrier integrity by targeting tight junctions through IL-13 in asthmatic patients","volume":"141","author":"Sugita","year":"2018","journal-title":"J. Allergy Clin. Immunol."},{"key":"10.1016\/j.cyto.2024.156814_bb0165","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0003331","article-title":"The IL-1-like cytokine IL-33 is constitutively expressed in the nucleus of endothelial cells and epithelial cells in vivo: a novel \u2018alarmin\u2019?","volume":"3","author":"Moussion","year":"2008","journal-title":"PLoS One"},{"key":"10.1016\/j.cyto.2024.156814_bb0170","doi-asserted-by":"crossref","first-page":"153","DOI":"10.2500\/aap.2018.38.4105","article-title":"Interleukin 33 and interleukin 4 regulate interleukin 31 gene expression and secretion from human laboratory of allergic diseases 2 mast cells stimulated by substance P and\/or immunoglobulin E","volume":"39","author":"Petra","year":"2018","journal-title":"Allergy Asthma Proc."},{"key":"10.1016\/j.cyto.2024.156814_bb0175","doi-asserted-by":"crossref","first-page":"448","DOI":"10.1016\/j.jaci.2013.10.048","article-title":"A sensory neuron-expressed IL-31 receptor mediates T helper cell-dependent itch: involvement of TRPV1 and TRPA1","volume":"133","author":"Cevikbas","year":"2014","journal-title":"J. Allergy Clin. Immunol."},{"key":"10.1016\/j.cyto.2024.156814_bb0180","doi-asserted-by":"crossref","first-page":"464","DOI":"10.1111\/j.1600-0625.2010.01067.x","article-title":"Increased levels of serum IL-31 in chronic spontaneous urticaria","volume":"19","author":"Raap","year":"2010","journal-title":"Exp. Dermatol."},{"key":"10.1016\/j.cyto.2024.156814_bb0185","doi-asserted-by":"crossref","first-page":"454","DOI":"10.1111\/jdv.12831","article-title":"Successful omalizumab treatment in chronic spontaneous urticaria is associated with lowering of serum IL-31 levels","volume":"30","author":"Altrichter","year":"2016","journal-title":"J. Eur. Acad. Dermatol."},{"key":"10.1016\/j.cyto.2024.156814_bb0190","doi-asserted-by":"crossref","first-page":"8087274","DOI":"10.1155\/2023\/8087274","article-title":"Effects of Omalizumab on serum levels of substance P, calcitonin gene-related peptide, neuropeptide Y, and Interleukin-31 in patients with chronic spontaneous Urticaria","volume":"2023","author":"Boyvadoglu","year":"2023","journal-title":"Mediat. Inflamm."},{"key":"10.1016\/j.cyto.2024.156814_bb0195","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1016\/j.coi.2018.09.002","article-title":"IL-6: a cytokine at the crossroads of autoimmunity","volume":"55","author":"Jones","year":"2018","journal-title":"Curr. Opin. Immunol."},{"key":"10.1016\/j.cyto.2024.156814_bb0200","doi-asserted-by":"crossref","first-page":"1386","DOI":"10.1111\/j.1365-2222.2011.03789.x","article-title":"Plasma IL-6 concentration correlates with clinical disease activity and serum C-reactive protein concentration in chronic urticaria patients","volume":"41","author":"Kasperska-Zajac","year":"2011","journal-title":"Clin. Exp. Allergy"},{"key":"10.1016\/j.cyto.2024.156814_bb0205","doi-asserted-by":"crossref","first-page":"1279139","DOI":"10.3389\/fimmu.2023.1279139","article-title":"Key genes and immune infiltration in chronic spontaneous urticaria: a study of bioinformatics and systems biology","volume":"14","author":"Su","year":"2023","journal-title":"Front. Immunol."},{"key":"10.1016\/j.cyto.2024.156814_bb0210","doi-asserted-by":"crossref","first-page":"625","DOI":"10.1016\/j.micinf.2009.04.003","article-title":"IL-17 and Th17 cells in human inflammatory diseases","volume":"11","author":"Miossec","year":"2009","journal-title":"Microbes Infect."}],"container-title":["Cytokine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1043466624003181?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1043466624003181?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,12,14]],"date-time":"2024-12-14T15:22:06Z","timestamp":1734189726000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1043466624003181"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,1]]},"references-count":42,"alternative-id":["S1043466624003181"],"URL":"https:\/\/doi.org\/10.1016\/j.cyto.2024.156814","relation":{},"ISSN":["1043-4666"],"issn-type":[{"value":"1043-4666","type":"print"}],"subject":[],"published":{"date-parts":[[2025,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Predictive cytokines of omalizumab in the treatment of chronic spontaneous urticaria","name":"articletitle","label":"Article Title"},{"value":"Cytokine","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.cyto.2024.156814","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 The Authors. Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}],"article-number":"156814"}}